近日，博纳西亚(杭州)医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国 际、工银国际为其联席保荐人。 招股书显示，这家总部位于杭州的临床合同研究组织(CRO)致力于通过数字化赋能创新药临床研究，深 耕肿瘤及自身免疫性疾病两大领域，于2024年已取得约6729.1万元盈利。不过，与此同时，公司现金 流、应收账款状况面临考验，且公司市场份额并不占优，或将成为市场投资者担忧的因素。 在巨头林立的CRO行业，博纳西亚讲述的"小而美"故事，能否收获投资者青睐? 2025年业绩回暖 毛利率稳步上行 与行业平均水平相比，公司贸易应收款周转天数明显偏高。从2023年的44天，飙升至2024年的65天， 2025年前9个月进一步攀升至89天，远高于行业平均60天左右的水平。 应收款周转天数的快速上升表明，一方面，在生物医药融资环境虽然回暖但仍偏谨慎的背景下，博纳西 亚下游客户中资金紧张的生物医药企业占比可能上升，导致付款周期拉长;另一方面，博纳西亚的行业 地位处于弱势，也导致公司议价权相对薄弱。 据招股书披露，就2024年来自临床CRO服务的收入而言，博纳西亚在总部位于中国的市场参与者中排 名第14位，市 ...

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The clinical CRO industry is experiencing a recovery, with increasing demand driven by the global rise in innovative drug financing and the expansion of clinical trial outsourcing. The company is expected to benefit from this trend, with a significant increase in new orders and market share [8]. - The company has established itself as a leader in the clinical CRO market in China, with its market share rising from 8.7% in 2019 to 12.8% in 2023. This growth is attributed to the optimization of supply and the company's strong competitive position [8]. - The company's revenue and profit forecasts indicate a recovery, with expected revenues of 71.29 billion yuan in 2025, 80.19 billion yuan in 2026, and 93.27 billion yuan in 2027, alongside a substantial increase in net profit [8]. Summary by Sections Company Overview - Founded in 2004, the company has grown to become a leading clinical CRO in China, providing comprehensive services for the biopharmaceutical industry through self-built and acquired networks [14]. - The company's ownership structure is stable, with key founders holding significant shares and a management team experienced in top-tier biopharmaceutical companies [15]. Financial Analysis - The company has experienced revenue growth from 254 million yuan in 2012 to 6.603 billion yuan in 2024, with a compound annual growth rate (CAGR) of 28.5%. However, growth has slowed in 2023 and 2024 due to market conditions [19]. - The company’s gross margin has faced pressure, but a recovery is anticipated in 2026 as low-priced orders are cleared and new orders increase [22]. Industry Outlook - The global demand for CRO services is expected to grow, with the penetration rate of outsourced pharmaceutical R&D projected to exceed 50% by 2024 and reach approximately 65% by 2033 [43]. - The number of CRO companies in China has decreased significantly due to market consolidation, enhancing the competitive landscape for leading firms like the company [52]. Business Segments - The company operates primarily in two segments: Clinical Trial Technical Services (CTS) and Clinical Trial Related Services and Laboratory Services. CTS is the cornerstone of the business, covering all phases of clinical trials [54]. - The company has a strong international presence, with operations in 33 countries and a growing number of overseas projects, reflecting its commitment to global expansion [63].

2月11日，港交所官网显示，博纳西亚（杭州）医药科技股份有限公司（以下简称"博纳西亚"）正式向港交所主板递 交上市申请，兴证国际、工银国际为其联席保荐人。 博纳西亚的服务范围涵盖整个临床开发过程，包括新药临床试验申请（IND）、I-IV期临床研究、新药上市申请 （NDA）注册申报以及FSP服务及其他服务。 招股书显示，博纳西亚在2026年1月22日刚刚改制为股份有限公司，并更名。截至最后实际可行日期，公司创始 人、董事会主席兼总经理赵敏先生直接持股61.01%，并通过博达创新（持股12.99%）及博华创新（持股4.33%）间 接持股。赵敏合计控制公司已发行股本总额约78.33%，处于绝对控股地位，为公司实控人。 在招股书中，博纳西亚亮出了一份毛利率、净利率、人均创收均碾压行业平均水平的成绩单。 | 【繼續】的【贈獲】數目 : [編纂]股H股(視乎[編纂] | | | --- | --- | | 行使與否而定) | | | [編纂]數目 | .. [編纂]股H股(可予[編纂]) | | [編纂]數目 | : [編纂]股H股(可予[編纂]及 | | 視乎[編纂]行使與否而定) | | | 最高[編纂] : 每股H ...

深圳商报·读创客户端记者 李耿光 2月11日，港交所官网显示，博纳西亚（杭州）医药科技股份有限公司（以下简称"博纳西亚"）正式向港交所主板递 交上市申请，兴证国际、工银国际为其联席保荐人。 | [編纂]的[編纂]數目 : [編纂]股H股(視乎[編纂] | | | | --- | --- | --- | | 行使與否而定) | | | | [編纂]數目 | .. | [編纂]股H股(可予[編纂]) | | [編纂]數目 | | :「編纂]股H股(可予[編纂]及 | | 視乎[編纂]行使與否而定) | | | | 最高[編纂] : 每股H股[編纂]港元,另加1% | | | | 經紀佣金、0.0027%證監曾交易 | | | | 徵費、0.00015% 會財局交易徵費及 | | | | 0.00565%聯交所交易費(須於[編纂 | | | | 時以港元繳足,多繳款項可予退還 | | | | 面值 | .. | 每股H股人民幣[0.10]元 | | [編纂] : [編纂] | | | 招股书披露，博纳西亚是一家总部位于中国杭州的临床合同研究组织（CRO）机构，致力于通过数字化赋能创新药 临床研究。公司的主营业务是提 ...

行使與否而定) 視乎[編纂]行使與否而定) 最高[編纂] : 每股H股[編纂]港元,另加1% 据港交所2月11日披露，博纳西亚（杭州）医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国际、工银国际为其联席 保荐人。招股书披露，博纳西亚是一家总部位于中国杭州的临床合同研究组织（「CRO」）机构，致力于通过数字化赋能创新药临床研究。公 司的核心业务是为国内外制药及生物技术公司提供临床试验技术服务，旨在加速化学药物和生物制品的研发及商业化进程。 PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd. 博納西亞(杭州)醫藥科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) [編纂] [編纂]的[編纂]數目 : [編纂]股H股(視乎[編纂] 聯席保薦人·[編纂]·[編纂]· [繼臺] ICBC (E) 工银国际 「編纂]數目 :「編纂]股H股(可予[編纂]) 「編纂]股H股(可予[編纂]及 [編纂]數目 0.00565%聯交所交易費(須於[編纂] 時以港元繳足,多繳款項可予退還) 面值 : 每股H股人民幣[0.10]元 經紀佣金、0.0 ...

[編纂]的[編纂]數目 : [編纂]股H股(視乎[編纂] 行使與否而定) 据港交所2月11日披露，博纳西亚(杭州)医药科技股份有限公司(简称：博纳西亚)向港交所主板递交上市申请，兴证国际、工银国际为其联席保 荐人。招股书披露，博纳西亚是一家总部位于中国杭州的临床合同研究组织("CRO")机构，致力于通过数字化赋能创新药临床研究。公司的核 心业务是为国内外制药及生物技术公司提供临床试验技术服务，旨在加速化学药物和生物制品的研发及商业化进程。 PANACRO (Hangzhou) Pharmaceutical Technology Co., Ltd. 博納西亞(杭州)醫藥科技股份有限公司 (於中華人民共和國註冊成立的股份有限公司) [編纂] 經紀佣金、0.0027%證監會交易 徵費、0.00015%會財局交易徵費及 [編纂] : [編纂] ICBC (E) 工银国际 「編纂]數目 :「編纂]股H股(可予[編纂]) 「編纂]股H股(可予[編纂]及 [編纂]數目 0.00565%聯交所交易費(須於[編纂] 時以港元繳足,多繳款項可予退還) 面值 : 每股H股人民幣[0.10]元 視乎[編纂]行使與否而定) 最高[編纂 ...

2月3日，泰格医药涨4.97%，成交额10.32亿元。两融数据显示，当日泰格医药获融资买入额5393.21万 元，融资偿还5727.85万元，融资净买入-334.64万元。截至2月3日，泰格医药融资融券余额合计6.31亿 元。 截至9月30日，泰格医药股东户数4.84万，较上期减少6.01%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，泰格医药实现营业收入50.26亿元，同比减少0.82%；归母净利润10.20亿元，同比增长 25.45%。 分红方面，泰格医药A股上市后累计派现24.58亿元。近三年，累计派现11.54亿元。 机构持仓方面，截止2025年9月30日，泰格医药十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股4836.25万股，相比上期增加2509.69万股。中欧医疗健康混合A（003095）位居第四大流 通股东，持股2885.17万股，相比上期增加121.78万股。华宝中证医疗ETF（512170）位居第五大流通股 东，持股1456.80万股，相比上期减少266.25万股。易方达创业板ETF（159915）位居第八大流通股东， 持股1125.86万股，相比上期减少 ...

Core Viewpoint - On January 15, Tiger Med experienced a slight decline of 0.38% with a trading volume of 700 million yuan, indicating a low level of financing and margin trading activity [1][2]. Financing Summary - On January 15, Tiger Med had a financing buy amount of 39.99 million yuan and a financing repayment of 40.44 million yuan, resulting in a net financing outflow of 446,300 yuan. The total financing and margin trading balance reached 675 million yuan [1]. - The current financing balance is 673 million yuan, which accounts for 1.45% of the circulating market value, indicating a low level compared to the past year [1]. Margin Trading Summary - On January 15, Tiger Med repaid 100 shares in margin trading and sold 1,300 shares, with a selling amount of 81,600 yuan based on the closing price. The margin trading balance is 1.59 million yuan, which is also low compared to the past year [1]. Company Overview - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, is located in Hangzhou, Zhejiang Province. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products [2]. - The main business revenue composition includes clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other services (2.19%) [2]. Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%. However, the net profit attributable to the parent company was 1.020 billion yuan, reflecting a year-on-year increase of 25.45% [2]. Dividend Information - Since its A-share listing, Tiger Med has distributed a total of 2.458 billion yuan in dividends, with 1.154 billion yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, Tiger Med had 48,400 shareholders, a decrease of 6.01% from the previous period. The average circulating shares per person remained at 0 shares [2][3]. - The second-largest circulating shareholder is Hong Kong Central Clearing Limited, holding 48.3625 million shares, an increase of 25.0969 million shares from the previous period [3].

Core Viewpoint - Tiger Med's stock price has shown significant growth in recent months, with a year-to-date increase of 13.28% and a 30.31% rise over the past 20 trading days [1]. Group 1: Stock Performance - As of January 14, Tiger Med's stock price reached 64.23 CNY per share, with a trading volume of 1.49 billion CNY and a market capitalization of 55.304 billion CNY [1]. - The stock experienced a 2.11% increase during the trading session on January 14 [1]. - The stock has seen a 6.52% increase over the last five trading days and an 18.77% increase over the last 60 days [1]. Group 2: Financial Performance - For the period from January to September 2025, Tiger Med reported a revenue of 5.026 billion CNY, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.020 billion CNY [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Tiger Med was 48,400, a decrease of 6.01% from the previous period [2]. - The company has distributed a total of 2.458 billion CNY in dividends since its A-share listing, with 1.154 billion CNY distributed over the last three years [3]. - The second-largest shareholder, Hong Kong Central Clearing Limited, increased its holdings by 25.097 million shares to 48.3625 million shares [3].

Group 1 - The core viewpoint of the news is that Tigermed has experienced fluctuations in its stock price, with a recent increase of 2.03% and a total market capitalization of 44.196 billion yuan [1] - As of September 30, 2025, Tigermed reported a revenue of 5.026 billion yuan, a year-on-year decrease of 0.82%, while the net profit attributable to shareholders increased by 25.45% to 1.02 billion yuan [2] - The company has distributed a total of 2.458 billion yuan in dividends since its A-share listing, with 1.154 billion yuan distributed in the last three years [3] Group 2 - Tigermed operates in the medical and biological sector, specifically in medical research outsourcing, and is involved in various concept sectors including CRO, medical devices, and internet healthcare [2] - The company has seen a decrease in the number of shareholders, with 48,400 shareholders as of September 30, 2025, a reduction of 6.01% from the previous period [2] - The top shareholders include Hong Kong Central Clearing Limited and several ETFs, with notable changes in their holdings compared to the previous period [3]